| US 7,462,596 B2 | ||
| Pharmaceutical compositions comprising mannose binding lectin | ||
| Jesper Lund Larsen, København Ø (Denmark); and Leif Kongerslev, Birkerød (Denmark) | ||
| Assigned to Natimmune A/S, Copenhagen (Denmark) | ||
| Filed on Mar. 14, 2003, as Appl. No. 10/388,322. | ||
| Claims priority of application No. 2002 00414 (DK), filed on Mar. 15, 2002. | ||
| Prior Publication US 2004/0006009 A1, Jan. 08, 2004 | ||
| Int. Cl. A61K 38/16 (2006.01) | ||
| U.S. Cl. 514—8 | 106 Claims |
| 1. A stable, sterile filtered, pharmaceutically acceptable composition comprising
at least 750 μg/ml mannan binding lectin (MBL) and/or at least one MBL functional homologue which is at least 95% identical
with SEQ ID NO:1, or a salt thereof, and an MBL-stabilizing amount of a divalent cation,
wherein said composition is free of any protein containing stabiliser, and wherein each said MBL functional homologue has
C4 activation activity.
|